12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SYL040012: Phase II started

Sylentis said it began a placebo-controlled, dose-ranging, European Phase II trial to evaluate daily SYL040012 eye drops for 14 days in 80...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >